Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Commercial

With oral obesity race underway, all eyes are on Lilly’s Foundayo launch

 April 10, 2026

BioSpace

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill.

CommercialMetabolic & GLP-1Read full story

Post navigation

Senju launches first-in-class dry eye disease drug in Japan →
← RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com